Defining the functional role of NaV1.7 in human nociception by McDermott, Lucy A. et al.
ArticleDefining the Functional Role of NaV1.7 in Human
NociceptionHighlightsd Patients with CIP due to NaV1.7 mutations have a functional
absence of nociceptors
d Lack of nociceptive drive is reflected in a reduced cortical
response to capsaicin
d Patient iPSC nociceptors show reduced excitability,
especially to ramp stimuli
d Gene-edited iPSC nociceptors represent a valuable analgesic
drug screening platformMcDermott et al., 2019, Neuron 101, 905–919
March 6, 2019 ª 2019 The Author(s). Published by Elsevier Inc.
https://doi.org/10.1016/j.neuron.2019.01.047Authors
Lucy A. McDermott, Greg A. Weir,
Andreas C. Themistocleous, ...,
Irene Tracey, Jordi Serra,
David L. Bennett
Correspondence
david.bennett@ndcn.ox.ac.uk
In Brief
Gene mutations associated with painless
phenotypes offer great insight for
analgesic development. Using a multi-
modal approach, McDermott et al. show
that mutations in the voltage-gated
sodium channel NaV1.7 cause congenital
insensitivity to pain due to a lack of
functional nociceptors.
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Loss-of-function mutations in NaV1.7 cause congen-
ital insensitivity to pain (CIP); this voltage-gated so-
dium channel is therefore a key target for analgesic
drug development. Utilizing a multi-modal approach,
we investigated howNaV1.7mutations lead to human
pain insensitivity. Skin biopsy andmicroneurography
revealed an absence of C-fiber nociceptors in CIP
patients, reflected in a reduced cortical response to
capsaicin on fMRI. Epitope tagging of endogenous
NaV1.7 revealed the channel to be localized at the
soma membrane, axon, axon terminals, and the no-
des of Ranvier of induced pluripotent stem cell
(iPSC) nociceptors. CIP patient-derived iPSC noci-
ceptors exhibited an inability to properly respond to
depolarizing stimuli, demonstrating that NaV1.7 is a
key regulator of excitability. Using this iPSC nocicep-
tor platform, we found that some NaV1.7 blockers un-
dergoing clinical trials lack specificity. CIP, therefore,
arises due to a profound loss of functional nocicep-
tors, which is more pronounced than that reported
in rodent models, or likely achievable following acute
pharmacological blockade.
INTRODUCTION
Bi-allelic inactivating mutations in SCN9A, which encodes the
voltage-gated sodium channel (VGSC) NaV1.7, result in the strik-
ing clinical phenotype of congenital insensitivity to pain (CIP)
(Cox et al., 2006; Goldberg et al., 2007). These individuals do
not perceive pain in response to noxious stimuli (Bennett and
Woods, 2014), be it mechanical, thermal, or chemical in form.
Conversely, mutations that cause gain of function in NaV1.7
have been shown to cause Mendelian human pain disorders
such as inherited erythromelalgia (Yang et al., 2004; Dib-Hajj
et al., 2005) and paroxysmal extreme pain disorder (FertlemanNeuron 101, 905–919, M
This is an open access article undet al., 2006). Gain-of-function variants were also recently associ-
ated with more common acquired pain disorders such as small
fiber neuropathy (Faber et al., 2012) and painful diabetic neurop-
athy (Blesneac et al., 2018).
NaV1.7 is highly enriched in nociceptive and sympathetic neu-
rons of the peripheral nervous system (Toledo-Aral et al., 1997).
NaV1.7 is also expressed in the brain in subcortical structures,
including the thalamus, medial amygdala, hypothalamus, and
the axons of olfactory epithelium projecting to the olfactory
bulb (Kanellopoulos et al., 2018; Branco et al., 2016). Interest-
ingly, the only other clinical feature of bi-allelic loss-of-function
(LOF) NaV1.7 mutations is anosmia (Weiss et al., 2011). These
findings have led to extensive interest in selectively targeting
NaV1.7 as a means to develop novel analgesics.
Multiple drug development programs have been initiated,
including small molecule blockers (Zakrzewska et al., 2017;
Cao et al., 2016) and biologic approaches (Lee et al., 2014).
Channel selectivity would be highly desirable but is challenging
due to the homology of different VGSCs. Non-specific blockers
of VGSCs, such as some antiepileptic drugs, are currently
used as analgesics; however, the indiscriminate targeting ofmul-
tiple VGSCs in the heart and/or CNS often lead to significant
dose-limiting side effects. A critical barrier to drug development
is our current lack of understanding of the mechanisms underly-
ing CIP. We do not yet appreciate the locus of action, and this
has important implications for whether novel NaV1.7 blockers
need to cross the blood-brain barrier. It is also unclear whether
there are developmental effects on the structure or function of
the sensory nervous system, which would make the CIP pheno-
type unlikely to be replicated, even by highly potent acute phar-
macological blockade.
In rodent, NaV1.7 is expressed in the peripheral terminals,
axon, soma, and central terminals of sensory neurons (Kanello-
poulos et al., 2018; Black et al., 2012). Mutant mouse models
in which NaV1.7 is globally ablated or conditionally ablated in
subsets of sensory neurons have been generated (Nassar
et al., 2004; Gingras et al., 2014; Hoffmann et al., 2018). These
show reduced (although in some cases not absent) reflex
withdrawal responses to a broad range of acute noxious
thermal, mechanical, and chemical stimuli on behavioral testing.arch 6, 2019 ª 2019 The Author(s). Published by Elsevier Inc. 905
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Interestingly, not all the reduction in pain behavior (i.e., thermal
hypoalgesia) appears to be autonomous to sensory neurons
but may also involve interaction with the sympathetic nervous
system (Minett et al., 2012). Mice lacking NaV1.7 in sensory neu-
rons also show reduced hypersensitivity to select neuropathic
pain and inflammatory pain models (Minett et al., 2014). Cuta-
neous innervation by nociceptors is normal in mice with global
ablation of NaV1.7 (Gingras et al., 2014).
A number of mechanisms, which are not mutually exclusive,
have been proposed for this behavioral phenotype. Channel ki-
netics could position NaV1.7 as a threshold channel amplifying
sub-threshold depolarizations in nociceptor terminals and by
virtue conferring a critical role for NaV1.7 in action potential elec-
trogenesis. NaV1.7 may also be necessary for action potential
propagation along axons and neurotransmitter release at central
terminals in an analogous fashion to the olfactory system (Weiss
et al., 2011). Finally, NaV1.7 may intersect with other signaling
systems, such as endogenous opioids, which are upregulated
in the absence of NaV1.7 and thought to feedback onto dorsal
root ganglion (DRG) neurons and/or terminals to suppress excit-
ability (Minett et al., 2015).
There remains an important need to better characterize
dysfunction of the somatosensory nervous system in humans
with CIP. In rodent DRG neurons, slowmembrane depolarization
can trigger excitatory ramp currents, driven byNaV1.7 activation,
which occur as a result of the channel’s slow closed-state inac-
tivation (Cummins et al., 1998). These currents are considered
important in amplifying small sub-threshold depolarizing stimuli
and thereby increasing the likelihood of an action potential being
generated (Dib-Hajj et al., 2013). One recent study using cadav-
eric human DRG cells from previously healthy donors found a
lack of low-threshold excitatory ramp currents (Zhang et al.,
2017). The authors concluded that there may be a relative dearth
of NaV1.7 in human DRG neurons, and although NaV1.7 makes a
significant contribution to the TTX-sensitive sodium current in ro-
dents, this may not be the case in humans. However, this conclu-
sion is in contrast to another study that foundNaV1.7mRNA to be
the predominantly expressed VGSC in human DRG tissue
(Chang et al., 2018). Zhang et al. (2017) also questioned the
selectivity of pharmacological tools to study human NaV1.7,
but they did not have access to neurons lacking NaV1.7 to
conclusively determine this.
The techniques available to study the detailed structure and
function of the nociceptive system in humans have recently
advanced. We have therefore adopted a multi-modal approach
including sensory profiling, microneurography, functional brain
imaging, and human induced pluripotent stem cell (iPSC) models
combined with genome engineering to detail the functional role
of NaV1.7 in the human nociceptive system.
RESULTS
Sensory Profile of CIP Participants
We recruited three CIP participants to assess sensory nerve
function (Figure 1; Table 1). All study participants had confirmed
compound heterozygous mutations in SCN9A that were pre-
dicted to cause loss of protein function (Table S1). A summary
of their clinical assessment is found in Table 1. All three partici-906 Neuron 101, 905–919, March 6, 2019pants reported multiple painless injuries, including painless frac-
tures, from childhood. On clinical examination, the participants
were anosmic and did not feel pinprick as a painful sensation
and thus conformed to the typical clinical presentation of
SCN9A-related CIP (Cox et al., 2006; Weiss et al., 2011). Quan-
titative sensory testing (QST) confirmed the insensitivity to pain
phenotype as neither noxious temperature nor noxious mechan-
ical stimuli were felt as painful (Figure 1A). Cold and warm detec-
tion thresholds in both the hand and the foot were reduced when
compared to the normative range of the German Neuropathic
Pain Consortium, and thermal sensory limen were also impaired
(Figure 1A), indicative of thermal hypoesthesia. Mechanical and
vibration detection thresholds were normal (Figure 1A). Thus,
theQST data showed impairment of small fiber functionwith pre-
served large fiber function.
Topical application of algogens or pruritogens to the skin acti-
vates cutaneous chemo-sensitive C-fibers and induces release
of neuropeptides, causing a neurogenic flare response and re-
sulting in the perception of pain or itch (Groetzner and Weidner,
2010). Histamine (Figures 1B, S1A, and S1B) and mustard oil
(Figures 1C, S1C, and S1D) application to the volar surface of
the forearm elicited flare responses in all CIP participants. The
participants did not report pain or pruritus. This is in contrast
to a cohort of healthy controls (n = 10) who unanimously reported
a painful ‘‘stinging’’ and ‘‘burning’’ sensation when mustard
oil was applied, with a mean maximal visual analog scale
(VAS) pain score (95% confidence interval [CI]) of 3.5 (1.8:5.2)
(p = 0.03, CIP VAS versus healthy control, Student’s unpaired
t test). The histamine flare was blocked when local anesthetic
was infiltrated before iontophoresis of the histamine (Figure S1E),
indicating that it was neurally mediated. The ability to generate a
flare response in CIP participants suggests that at least some
cutaneous nerve fibers responsive to noxious stimuli can
generate short-range action potentials.
Nerve conduction studies from motor and sensory nerves of
the lower limbs, except for one participant, all fell within norma-
tive reference ranges (Tables 1 and S2). One participant had
small-amplitude sural sensory nerve action potentials. The re-
cordings were difficult due the multiple injuries that the partici-
pant had previously sustained to his lower limbs. The reduced
amplitudes may therefore be due to past trauma. Sensory nerve
excitabilitymeasurements recorded from themedian nerve all fell
within the 95%CIs for healthy study participant parameters (Fig-
ure S2). Therefore, functional neurophysiological assessment of
large fiber function did not reveal any abnormalities. The intra-
epidermal nerve fiber density (IENFD) measurements from the
lower leg of our study participants were below the 0.05 quantile
for published age- and gender-matched normative data in all
cases (Figures 1D–1F). We did, however, observe deeper dermal
fibers in all participants (Figure 1E). Therefore, IENFD measure-
ments showed evidence of small fiber pathology. In addition,
we also found absent or markedly reduced intra-epidermal nerve
fibers at theproximal thigh in all participants (Table 1; FigureS1F).
Patient SCN9A Mutations Result in Loss of Channel
Function
Only one mutation (c.2691G > A p.Y897X) in our patient cohort
has previously been described and functionally characterized
Figure 1. Structure and Function of the
Somatosensory Nervous System in CIP
Patients
(A) Scatterplot of Z scores for QST parameters in
study participants recorded from the dorsumof the
hand and foot. The participants did not feel any
pain in response to noxious stimuli and stimuli
reached ‘‘cut off’’ (CO on figure). Error bars
represent mean ± SD. WDT, warm detection
threshold; CDT, cold detection threshold; TSL,
thermal sensory limen; CPT, cold pain threshold;
HPT, heat pain threshold; MDT, mechanical
detection threshold; VDT, vibration detection
threshold; MPT, mechanical pain threshold; MPS,
mechanical pain sensitivity; WUR, wind-up ratio;
PPT, pressure pain threshold.
(B) Histamine flare response on the forearm of a
CIP participant. ‘‘X’’ marks the area of iontopho-
resis and the green circle the extent of the flare.
(C) Mustard oil flare response on the forearm of a
CIP participant. ‘‘M’’ marks the area of mustard oil
application and the green circle the extent of the
flare response.
(D and E) Skin biopsy taken from the lower leg of a
healthy control (D) study participant (E) demon-
strating the absence of intra-epidermal nerve fi-
bers and the presence of dermal fibers in the CIP
study participant. The arrows indicate where the
nerve fibers cross between the epidermis and
dermis. The dashed line represents the division
between the epidermis and dermis. Scale bars
represent 50 mm.
(F) Quantification of intra-epidermal nerve fibers of
skin biopsies taken from the lower leg and proximal
thigh from CIP participants. The dashed line rep-
resents the lowest 0.05 quantile for published age-
and gender-matched normative data. IENFD,
intra-epidermal nerve fiber density.
See also Figures S1 and S2.(Cox et al., 2006). We heterologously expressed the novel
NaV1.7 variants (Figure 2A) in HEK293T cells and used whole-
cell patch-clamp recordings to evaluate their impact on channel
biophysics. Representative whole-cell voltage-clamp currents
from transfected cells are shown in Figure 2B. All the mutations
drastically reduced NaV1.7 current. FS1773 mutation resulted in
an 8-fold reduction in the current density of the channel (Figures
2B and 2C). The R896W, R830X, and G1725R showed a pro-
found loss of function with negligible current densities (Fig-
ure 2C). All CIP mutations therefore caused a significant loss of
conductance compared to control, consistent with almost com-
plete loss of channel function.
C-Fiber Nociceptors Are Not Detected by
Microneurography
A total of 38 C-fibers were recorded and analyzed from three of
the subjects (14 from 4 intraneural sites in patient CIP1, 7 from 3
intraneural sites in patient CIP2, and 17 from 6 intraneural sites in
patient CIP3). None of these recordings identified fibers with
properties consistent with C-nociceptors. The frequency of
different profiles of activity-dependent slowing (ADS) of
conduction velocity was: type 1 (C-nociceptors) 0 (0%), type 2
(thermoreceptors) 10/38 (26.3%), type 3 (low-threshold C-mech-anoreceptors) 5/38 (13.2%), and type 4 (sympathetic efferent)
23/38 (60.5%) (Figure 3). All intraneural sites showed ADS pro-
files with ‘‘plateau’’ units during 2Hz stimulation (see for compar-
ison Figure 3 in Serra et al., 1999, Figure 1 in Serra et al., 2004, or
Figure 1 in Campero et al., 2004). This frequency of sensory
afferent types was significantly different to normative data from
healthy patients (Serra et al., 1999; Campero et al., 2004), owing
to the lack of type 1 fibers (p < 0.001, Fisher’s exact test). There-
fore, there was a striking lack of ADS of conduction velocity pro-
files compatible with peripheral C-nociceptors. There were no
differences with historical ADS of conduction velocity data for
these three C-fiber types (Table S3).
Brain Activity Changes in Response to Capsaicin Are
Reduced in a CIP Patient
Despite the stark clinical phenotype of CIP, a previous study
failed to finddifferences inbrain activity ofCIPpatients compared
tohealthy controls in response toacute noxiousmechanical stim-
uli (Salomons et al., 2016). However, the method used for com-
parison in this study has been criticized, making the conclusions
from the original study less clear (B€uchel et al., 2016).
We sought to investigate tonic responses to an algogen
(capsaicin) using arterial spin labeling in one CIP participantNeuron 101, 905–919, March 6, 2019 907
Table 1. Summary of Clinical Findings and Special Investigations
CIP1 CIP2 CIP3
Age 31 34 44
Gender Male Male Female
History
Painless injuries
(e.g., fractures, burns)
Y Y Y
Congenital onset Y Y Y
Normal cognitive development Y Y Y
Self-mutilation Y N N
Absent visceral pain Y Y Y
Joint replacement Y N Y
Charcot joints Y Y Y
Affected siblings Y Y N
Examination
Anosmia Y Y Y
Normal autonomic function
(sweating, bowel function,
blood pressure)
Y Y Y
Corneal reflex intact Y Y Y
Normal motor examination Y Y Y
Normal deep tendon reflexes Y Y Y
Vibration, mechanical
detection, proprioception
normal
Y Y Y
Pin prick not felt as painful
nor sharp
Y Y Y
Bedside temperature normal N Y N
Investigations
Histamine flare Y Y Y
Mustard oil flare Y Y Y
Nerve conduction studies
normal
Na Y Y
Threshold tracking normal Y Y Y
fMRI N Y N
Microneurography Y Y Y
IENFD
Proximal thigh (fibers/mm) 0.2 0.00 0.00
Distal leg (fibers/mm) (0.05
quantile; median)
3.98 (5.3;
10.2)
0.00 (5.3;
10.2)
0.00 (5.7;
11.2)
N, no; Y, yes; ND, not done; IENFD, intra-epidermal nerve fiber density.
aSural amplitudes are reduced(CIP2) who was eligible for functional brain imaging. This
approach removes the confound of mechanical stimulation and
avoids the analysis and interpretative problems pointed out pre-
viously (B€uchel et al., 2016). Treatment of the CIP participant’s
skin with a 1% topical capsaicin cream failed to elicit similar re-
sponses to what is commonly reported in a healthy control (HC)
population. The participant reported no pain and no unpleasant-
ness associated with any of the experimental conditions tested
(NRS = 0). This was in contrast to the HC group, which found
the experience of capsaicin and thermal stimulation intensely908 Neuron 101, 905–919, March 6, 2019painful (NRS = 49.997 ± 3.525) (Figure 4A; *p < 0.001Mann-Whit-
ney U test). In CIP, the brain response to ‘‘thermal + capsaicin’’
versus ‘‘rest’’ was the only contrast that showed significant
changes in cerebral blood flow (CBF). Increased CBF was
observed in the primary somatosensory cortex (SI), the dorsal
anterior cingulate, and the posterior cingulate (mixed effects;
z > 3.1, p < 0.05) (Figure 4C). In healthy controls, significant in-
creases in CBF were observed in the primary and secondary so-
matosensory cortices, dorsal lateral prefrontal cortex, insula
(anterior, mid, and posterior), anterior cingulate, putamen, nu-
cleus accumbens, periaqueductal gray, and the cerebellum
(mixed effects; z > 3.1, p < 0.05) (Figure 4C). To confirm that
the changes observed during the capsaicin-evoked thermal con-
dition are related to distinct perceptual experiences in CIP
versus HC, we applied the neurological pain signature (NPS) to
these data. The NPS is a weighted multivariate brain activation
map that is strongly correlated with experimental physical pain
reports and can be applied to imaging data to predict the severity
of pain that was likely experienced during a scan (Wager et al.,
2013). For each subject, the NPS expression was calculated
by taking the dot product of the NPS and the contrast image
for ‘‘thermal + capsaicin > rest’’ condition. For CIP, the NPS
expression was generated from the mean of six repeated trials
of the ‘‘thermal + capsaicin > rest’’ conditions. For HC, the
NPS was derived from the mean across 12 subjects scanned
once. A comparison of the NPS response values observed was
significantly greater in HC compared to CIP (*p < 0.001 Mann-
Whitney U test) (Figure 4D). In effect, there was no overlap with
the NPS of brain activity from the CIP patient in response to
capsaicin-induced tonic heat hyperalgesia, whereas there was
overlap with the NPS of brain activity from HC.
NaV1.7 Is Robustly Expressed in iPSC Nociceptors and
Trafficked to Specific Neuronal Compartments
The directed differentiation of human iPSCs to nociceptors en-
ables functional modeling of CIP pathogenesis in vitro and
should provide significant insight into the role of NaV1.7 in noci-
ceptor physiology. We used the differentiation protocol
described by Chambers et al. (2012) to generate highly pure cul-
tures of neurons that express the sensory neuron marker Brn3a
(Figure 5A). Mature iPSC nociceptors are molecularly compara-
ble to human sensory neurons, capable of responding to noxious
stimuli, and exhibit mature electrophysiological characteristics
(Young et al., 2014; Chambers et al., 2012; Weir et al., 2017).
We further confirmed the molecular profile of our iPSC nocicep-
tors by performing RNA sequencing (RNA-seq). Principal-
component analysis demonstrated good clustering of iPSC
nociceptors with previously published studies (Schwartzen-
truber et al., 2018) and with hDRG data tissue (Ray et al., 2018)
(Figure S3A). iPSC nociceptors had high DRG neuronal signature
(compiled from enriched genes in hDRG tissue data) relative to
other tissues (Figure S3B). SCN9A expression was found to be
high and to a similar level to hDRG tissue (Figure S3C).
We then sought to examine the distribution of NaV1.7 protein
in iPSC nociceptors. Commercially available antibodies
targeting the human channel are poor, hampering efforts to
localize NaV1.7 protein. We therefore decided to tag endoge-
nous NaV1.7 using CRISPR-Cas9-mediated genome editing
Figure 2. CIP Mutations Result in Loss of
NaV1.7 Function
(A) Schematic of NaV1.7 channel topology. CIP
mutations are represented with orange dots.
(B) Representative currents elicited by a test po-
tential to 10 mV from a holding potential
of 100 mV for the wild-type (WT) (black), G1725R
(red), or FS1773 (blue) channels.
(C) Summarized data for whole-cell current density
elicited by a test potential to10mV from a holding
potential of100mV for theWT (474.2± 75pA/pF,
n = 17), R896W (7.6 ± 3.8 pA/pF, n = 9), R830X
(2.8. ± 0.9 pA/pF, n = 8), G1725R (15.7 ± 5.4 pA/
pF, n = 9), and FS1773 (62.2± 18.8, n = 8). Data are
presented as mean ± SEM. For all, ****p % 0.0001
compared with WT. One-way ANOVA followed by
Dunn’s multiple comparison test.(Cong et al., 2013). The highly antigenic epitope tag hemaggluti-
nin (HA) was knocked in frame to the C terminus of one SCN9A
allele (Figures 5B and S4), labeling all known functional coding
NaV1.7 transcripts.
We examined temporal changes in expression of NaV1.7
following differentiation and found marked differences in protein
expression and localization through maturation. NaV1.7 was ab-
sent in iPSC cultures but highly enriched in matured iPSC noci-
ceptors (Figure 5C). A low level of neuronal expression was
observed at 25 days in vitro (DIV); protein was restricted to the
cell body and concentrated in a peri-nuclear hemi-ring consis-
tent with endoplasmic reticulum (ER) retention (Figure 5D). In
contrast, in mature cultures (60 DIV), we observed a striking
enrichment in cell surface expression and staining that spanned
the entire axonal trajectory (Figure 5E). NaV1.7 has previously
been reported to localize to axon terminals in rodent DRG neu-
rons (Black et al., 2012). Consistent with this finding, staining re-
vealed enrichment of NaV1.7 in terminal structures of our iPSC
nociceptors (Figure 5F). We have previously established that
iPSC nociceptors can be efficiently myelinated in vitro when
cultured with rat Schwann cells (Clark et al., 2017). Having re-
vealed robust expression in unmyelinated human nociceptors,
we next examined NaV1.7 localization in myelinated co-cultures.
NaV1.7 could be seen localized to >90% of nodes of Ranvier in
myelinated axons—demarcated and flanked byMBP expression
(Figure 5G). In immature nodes present within the culture, chan-
nel distribution was concentrated but notably elongated, consis-
tent with the role of the paranodes in concentrating VGSC
localization at nodes (Amor et al., 2017) (Figure S5A). In vivo,
C-fibers associate with non-myelinating Schwann cells to form
Remak bundles, so we therefore also examined the influenceof Schwann cells on NaV1.7 localization
in co-cultures in which myelination was
not induced. Axons juxtaposed to aligned
non-myelinating Schwann cells exhibited
NaV1.7 localization along the length of
the neurite, similar to those cultured in
the absence of Schwann cells (Fig-
ure S5B). Together, these results demon-
strate that NaV1.7 is highly expressed iniPSC nociceptors and is trafficked appropriately to polarized
neuronal compartments.
NaV1.7 Modulates Excitability of iPSC Nociceptors
To investigate the contribution of NaV1.7 to nociceptor function,
we derived iPSC nociceptors from healthy and CIP donors. Two
clones were generated from patient CIP1 (clones cCIP1.1 and
cCIP1.2) and one clone from patient CIP2 (clone cCIP2). Three
clones generated from healthy control donors (HC1, HC2, and
HC3) were used as comparators. Human and rodent nociceptors
exhibit an inflection on the falling phase of the action potential
(Davidson et al., 2014; Ritter and Mendell, 1992); thus, to purify
recordings for mature iPSC nociceptors, we only included re-
cordings from neurons that demonstrated this feature (Fig-
ure 6A). Healthy and CIP iPSC nociceptors did not differ in their
resting state biophysical properties, including membrane poten-
tial (Table S4). When firing properties were assessed, CIP iPSC
nociceptors were found to be less excitable than healthy con-
trols. CIP iPSC nociceptors required increased current stimuli
to generate an action potential (healthy control 102.1 ± 4.2 pA
versus CIP 149.0 ± 10.0 pA, p < 0.001) (Figures 6A and S6A)
and fired fewer action potentials in response to prolonged
(500 ms) supra-threshold depolarization compared to healthy
controls (Figures 6B and S6B). To confirm that the observed hy-
poexcitability was due to a loss of NaV1.7 function, we used
CRISPR Cas9 to correct one SCN9A allele of clone CIP1.2,
reversing the c2488c > tmutation to thewild-type sequence (Fig-
ure S4). The corrected clone (corrected) demonstrated a
reduced rheobase compared to CIP1.2 (CIP1.2 142.7 ±
13.7 pA versus Corrected 97.1 ± 5.5 pA, p < 0.05) (Figures 6A
and S6A) that was similar to healthy controls (Figure 6A). TheNeuron 101, 905–919, March 6, 2019 909
Figure 3. Microneurographic Raster Plots
Illustrating Absence of ADS Profiles
Compatible with C-Nociceptors
(A–D) Several characteristic profiles of activity-
dependent slowing were identified in all three pa-
tients compatible with cold thermoreceptors (A),
low threshold C-mechanoreceptors (B, longer la-
tency), Ad fibers (B, shorter latencies), and several
sympathetic units (C and D). However, no ADS
profiles characteristic of C-nociceptors could be
identified.
(C) 5 different intraneural recording sites separated
by straight vertical lines in which only profiles of
ADS compatible with sympathetic units could be
recorded with an initial slowing followed by relative
speeding up of conduction velocity during a 2 Hz
stimulation period for 3 min (marked by filled bars).
(D) Magnified view of the square of the third intra-
neural recording site in (C). Right shows an
enlarged view of a sympathetic unit at initial la-
tency of 240 ms responding to a Valsalva maneu-
ver with a burst of activity.
Nomenclature of units follows that of Serra et al.
(1999, 2004).patient phenotype of reduced firing in response to prolonged su-
pra-threshold stimuli was not reversed by genetic correction
(Figures 6B and S6B). These results are consistent with the
recessive nature of CIP but suggest that to properly sustain re-
petitive firing, neurons require two functional copies of SCN9A.
To study the function ofNaV1.7 independent of inter-patient ge-
netic variability, we introduced a homozygous SCN9A frameshift
mutation (N842X) into a healthy control iPSC line (HC1), gener-
ating a NaV1.7 knockout (NaV1.7 KO) (Figure S4B). The de novo
mutation produces a premature stop codon in domain II of the
channel, leading to nonsense-mediated decay of the SCN9A
mRNA transcript (Figure S4C). NaV1.7 KO iPSCnociceptors reca-
pitulated the excitability changes observed in CIP lines, including
an increased rheobase (HC1 101.6 ± 5.3 pA versus NaV1.7 KO
145.5 ± 9.7 pA, p < 0.001) (Figures 6A and S6A) and a decreased
propensity to fire repetitively to supra-threshold stimulation (Fig-
ures 6B and S6B). A recent report proposed that loss of NaV1.7
leads to CIP at least partially through upregulation of endogenous
opioids, in particular proenkephalin (PENK) (Minett et al., 2015). In
the same study, naloxone (an opioid antagonist) was shown to
reduce analgesia in one CIP patient. We tested the efficacy of
naloxone treatment to normalize hypoexcitability of NaV1.7 KO
and found no effect on excitability measures of NaV1.7 KO neu-
rons (Figures S5E–S5G), demonstrating that opioid upregulation
was not driving the cellular phenotype that we observed. Consis-
tent with these results, we failed to detect PENKmRNA in healthy
control or NaV1.7KO iPSCnociceptors by qPCR (data not shown)
and did not detect meaningful expression (TPM < 1) in healthy
control iPSC nociceptors by RNA-seq analysis. Using whole-
cell voltage-clamp recordings, we found that the peak voltage-
gated sodium current was reduced by 23.89% in NaV1.7 KO
neurons compared to control (Figure 6C). This finding is in line910 Neuron 101, 905–919, March 6, 2019with studies in mouse assessing the contribution of mNaV1.7 to
voltage-gated sodium currents in small-diameter nociceptors
(Gingras et al., 2014;Minett et al., 2012). Stimulation of nociceptor
peripheral terminals likely results in generator potentials, which
slowly depolarize the membrane potential (Waxman 2006).
NaV1.7 displays slow closed-state inactivation, which enables
the channel to open in response to ramp depolarization and
initiate action potential generation (Cummins et al., 1998). To
test the hypothesis that NaV1.7 has a role in enabling neurons
to respond to slow depolarization, we injected ramps of supra-
threshold current with increasing gradients to mimic generator
potentials. NaV1.7 KO iPSC nociceptors were markedly less
responsive to ramp depolarization, especially to slower stimuli
(Figure 6D). Supporting this finding, CIP iPSC nociceptors were
also less responsive compared to healthy control (Figures S6C
and S6D). These data confirm the role of NaV1.7 in setting the
excitability state of iPSC nociceptors. Given the finding of
reduced IENFD in CIP patients and a previous report linking
NaV1.7 gain-of-function mutations to altered neurite outgrowth
of sensory neurons in vitro (Persson et al., 2013), we sought to
test whether iPSC nociceptors lacking NaV1.7 had a defect in
neurite outgrowth. Mature iPSC nociceptors develop substantial
projections during their time in culture (Figure S7A). We quantified
the area covered by these projections and found no difference
between NaV1.7 KO iPSC nociceptors and an isogenic control
line (HC1) (Figure S7B). Analogous to rodent DRG, when iPSC no-
ciceptors are dissociated, they regenerate neurites within hours
(Figure S7C). A similar proportion of nociceptors lacking NaV1.7
(CIP and NaV1.7 KO) generated neurite projections 12 h following
dissociation, compared to healthy control iPSC nociceptors
(c2 (2) = 3.425, p = 0.18) (Figure S7D). Of neurons that established
neurites, the average length was also not different between the
Figure 4. Reduced Cortical Response in CIP Patient to Capsaicin Challenge
(A) The comparison of the groupmean verbal pain intensity ratings collected during the ‘‘thermal + capsaicin’’ condition between theCIP and healthy controls (HC)
(Mann-Whitney U test, *p < 0.001). For HC, the error bars represent the SEM for the group (n = 12). Here, each healthy control participant was scanned once.
During this scan, a single trial testing the effects of each experimental condition once was observed for that subject. Multiple-repeat trials were not collected on
the HC cohort. For the single CIP patient, the error bars represent the SEM across repeated trials for that patient. The CIP patient was scanned twice. In each CIP
scan session, three repeat trials were collected for each experimental condition. A total of six trials were included in the analysis of the CIP patient.
(B) A schematic of the experimental paradigm used to image CIP patient. The schematic represents a single scan session. The four experimental conditions: Rest,
Thermal, Capsaicin, and Thermal + Capsaicin (‘‘Therm.+Cap.’’) are displayed as colored boxes. Three 5-min scan runs (i.e., r1, r2, r3) were collected for each
condition. The 25-min capsaicin onset phase is displayed as an inverted ‘‘z.’’ No FMRI data were collected here.
(C) The mean change in CBF elicited by the contrast of ‘‘thermal + capsaicin versus rest’’ for CIP (top row) and healthy controls (HC) (bottom row) (mixed effects;
z > 3.1, p < 0.05). Regions showing an increase in CBF during ‘‘thermal + capsaicin > rest’’ are displayed in red.
(D) Comparison of the group mean neurological pain signature (NPS) response values observed from the ‘‘thermal + capsaicin > rest’’ contrast images at the
subject level (Mann-Whitney U test, *p < 0.001). Data from repeated trials were processed as in (A).groups (Figure S7E). These results suggest that in vitro, loss of
NaV1.7 does not impact on intrinsic neurite outgrowth.
NaV1.7 KO as a Platform for Analgesic Drug Screening
Due to the genetic linkage between SCN9A LOF mutations and
CIP, developing specific inhibitors of NaV1.7 has become a ma-
jor goal of pharmaceutical companies seeking to generate
novel analgesics (Yekkirala et al., 2017). We reasoned that
our iPSC NaV1.7 KO lines would act as a platform to validate
the specificity of selective inhibitors. BII074 is a state-depen-
dent blocker that is considered selective for NaV1.7 (Zakrzew-
ska et al., 2017). BII074 was recently shown to be safe and to
have some efficacy in treating trigeminal neuralgia patients
(Zakrzewska et al., 2017). Clinically relevant concentrations of
BII074 dose-dependently increased the rheobase and reduced
the response to slow ramp depolarization of control (HC1) iPSC
nociceptors, consistent with block of NaV1.7 (Figures 7A and
7B). At concentrations observed in treated patient plasma
(2–10 mM) (Zakrzewska et al., 2017), BII074 had no effect on
rheobase of NaV1.7 KO neurons (Figure 7A). However,
selectivity was not observed at a moderately increased concen-
tration (25 mM), indicating that at these levels BII074 acts to
modulate non-NaV1.7 ion channels to influence excitability (Fig-
ure 7A). In vitro, BIIB074 preferentially inhibits firing in responseto high-frequency stimulation (Zakrzewska et al., 2017), which
may occur during paroxysmal pain attacks (as are frequently re-
ported in trigeminal neuralgia). To test high-frequency block, we
injected current steps of 150% rheobase magnitude at 20 Hz
and measured the ability of neurons to faithfully fire action po-
tentials in response to depolarization. NaV1.7 demonstrates
slow recovery from inactivation and therefore is not likely to
contribute to firing at this frequency (Herzog et al., 2003;
Dib-Hajj et al., 2013). BII074 dose-dependently induced high-
frequency firing block in control but also NaV1.7 KO neurons
(Figures 7C and 7D). This result suggests that BII074 inhibits
neuronal firing in the absence of NaV1.7, and at this concentra-
tion, the drug is acting on other targets.
PF-05089771 is a potent arylsulfonamide NaV1.7 inhibitor
(Alexandrou et al., 2016) undergoing clinical trials for painful dia-
betic neuropathy (McDonnell et al., 2018) and inherited erythro-
melalgia (Cao et al., 2016). At concentrations equivalent to the
free plasma concentration of PF-05089771 measured in treated
patients (Cao et al., 2016), PF-05089771 increased the rheobase
of control, but not NaV1.7 KO, neurons (Figure 7A). PF-05089771
did not affect high-frequency firing of either group of neurons at
any dose trialed (Figures 7C and 7D). These results suggest that
at the functional level, PF-05089771 does not impact iPSC noci-
ceptor excitability in the absence of NaV1.7.Neuron 101, 905–919, March 6, 2019 911
Figure 5. Genome Tagging of NaV1.7 Iden-
tifies Precise Subcellular Localization
(A) Representative split channel image of iPSC
nociceptors following differentiation, Brn3a (sen-
sory marker, red), DAPI (nuclei, blue), and NF200
(neurofilament, green).
(B) NaV1.7 membrane topology, the location of the
C-terminal HA epitope tag is indicated in yellow.
(C) Representative immunoblot of NaV1.7 protein
expression in SCN9A-HA iPSC and 60DIV SCN9A-
HA iPSC nociceptors; loading control b-actin.
(D and E) Immunocytological co-staining of 25 DIV
(D) and 60 DIV (E) iPSC nociceptors, NF200
(green), NaV1.7-HA (red), inset image depicts
separated channel NaV1.7-HA stain. Arrows in (E)
indicate marked cell surface expression.
(F) Representative image showing NaV1.7 expres-
sion in the axonal terminals of mature cultures,
F-Actin (green), NaV1.7-HA (red), inset; separated
channel image of NaV1.7-HA stain.
(G) NaV1.7 localized to the node of Ranvier (arrow)
in a myelinated co-culture, myelin basic protein
(green), NaV1.7-HA (red).
Scale bars, 25 mm (A) and 10 mm (D–G). See also
Figures S3 and S4.DISCUSSION
We have found that CIP in humans is due to a profound periph-
eral phenotype characterized by hypoexcitability of nociceptive
afferents but also important structural changes in these affer-
ents. We have used human iPSC-derived nociceptors to study
CIP at the cellular level and have shown that NaV1.7 is localized
to specialized neuronal compartments within nociceptors and is
critical in regulating excitability. We demonstrated that this
cellular model is helpful for probing selectivity of clinical com-
pounds aimed at inhibiting NaV1.7 and alleviating pain.
All CIP participants we studied are compound heterozygotes
for SCN9A mutations that drastically reduced the NaV1.7 cur-
rent. The R896W, R830X, and G1725R mutations were associ-
ated with almost total loss of channel function, while the
FS1773mutation, which resides in the C terminus of the channel,
resulted in an 8-fold reduction in the current density. Themajority
of previously characterized CIP NaV1.7 mutations result in
complete loss of channel function (Bennett and Woods, 2014);
however, one other recent paper has also reported a number
of CIP-associated SCN9Amutations in which some current is re-
tained (albeit significantly reduced) (Emery et al., 2015). The
FS1773 allele was paired (as a compound heterozygote) with
R830X, in which no current was observed. Therefore, very little
current is likely to be generated in vivo.
All participants had a clinical presentation consistent with CIP
secondary to bi-allelic SCN9A mutations. They had not experi-912 Neuron 101, 905–919, March 6, 2019enced pain at any point in their lives or
during our QST and algogen testing and
were anosmic. The sensory deficits were
not restricted to pain perception; partici-
pants were also hyposensitive to warming
and, to a lesser extent, cooling and hadimpaired thermal sensory limen. These modalities are mediated
by C and Ad thermoreceptors. It has previously been reported
that the flare response to histamine is preserved in these patients
(Goldberg et al., 2007), a finding that we replicated here. Previ-
ously unappreciated, however, is that although the neurogenic
flare is preserved, this stimulus does not evoke a perception of
itch in participants. This likely reflects the fact that there is a large
overlap in the primary afferent populations responding to algo-
gens and pruritogens, the majority of which express NaV1.7
(Schmelz et al., 2003; Usoskin et al., 2015). In preclinical models
of itch behavior, animals treated with a function-blocking anti-
body to NaV1.7 demonstrated less of a response to pruritic stim-
uli (Lee et al., 2014), and a recent report detailing adult-onset
ablation of NaV1.7 demonstrated a loss of itch behaviors in
response to histamine and chloroquine (Shields et al., 2018).
Large fiber-mediated modalities, such as detection of vibration
and light touch, were normal.
We undertook a number of electrophysiological tests studying
the impact of NaV1.7mutations on sensory nerve function in vivo.
VGSC mutations, as well as VGSC binding drugs and toxins,
have been shown to alter nerve excitability parameters in hu-
mans (Kiernan et al., 2005a, 2005b). We therefore undertook
sensory nerve excitability testing but did not find any significant
changes in the patients. The likely reason for this is that sensory
nerve action potentials (used as the outcome measure for
threshold tracking) are dominated by activity of large myelinated
axons. In rodents, only 15% of medium and large diameter
Figure 6. NaV1.7 Modulates Somal Excitability of Human Nociceptors
(A) Left: representative image showing action potential firing of a DIV 60 iPSC nociceptor to incremental current injections. Note the inflection on the falling phase
of the action potential. Right: rheobase derived from pooled data of healthy (119 cells), CIP (85 cells), corrected (33 cells), and NaV1.7 KO (45 cells) groups.
Kruskal-Wallis followed by post hoc Dunn’s test was used for all comparisons.
(B) Supra-threshold firing in response to prolonged depolarization current injection. Left: representative firing from a cell from each group. Right: pooled data from
the same cells as (A). Two-way ANOVA followed by post hoc Sidak’s multiple comparison test.
(C) Left: representative trace of voltage-gated sodium (NaV) current induced by step depolarization to 0mV from a holding potential of 100 mV. Right: quan-
tification of maximal NaV current comparing HC1 (n = 31) and NaV1.7 KO (n = 27) groups. Student’s unpaired t test.
(D) Left: representative traces of firing in response to 1 nA current injection given over 100–1000 ms in 100 ms increments. Right: quantification of firing across
different slopes of current injection. Two-way ANOVA followed by post hoc Sidak’s multiple comparison test. (HC1, 44 cells, and NaV1.7 KO, 54 cells). See also
Figure S6.
All data represent mean ± SEM pooled from at least independent differentiations. **p < 0.01, ***p < 0.001, ****p < 0.01 healthy versus CIP. #p < 0.05, ##p < 0.01,
###p < 0.001, ####p < 0.0001 NaV1.7 KO versus HC1 (parent clone).
+p < 0.05 corrected versus cCIP1.2 (parent clone).myelinated DRG neurons were reported to be NaV1.7 immunore-
active (Black et al., 2012). Furthermore, these neurons express
other TTX-s VGSCs such as NaV1.1 and NaV1.6. This finding
suggests that nerve excitability parameters are unlikely to be a
helpful biomarker in clinical trials of NaV1.7 blockers. We there-
fore proceeded to microneurography in which activity of small-
diameter sensory and sympathetic axons, C- and Ad-fibers,
can be directly assessed.
The findings on microneurography of the superficial peroneal
nerve were striking. Small fibers with the characteristics of C-
and Ad-low-threshold thermoreceptors, as well sympathetic ef-
ferents, could be readily recorded and identified based on the
profile of ADS of conduction velocity and natural activation using
previously well-established criteria (Serra et al., 1999, 2004;
Campero et al., 2004). However, we did not record any units
with the characteristics of C-fiber nociceptors. In healthy volun-
teers, the proportion of identified C-nociceptors using the same
searching technique as the one employed in this study amounts
to roughly 60% of all C-fibers in the superficial peroneal nerve
(Serra et al., 1999; Campero et al., 2004). It is important to note
that electrical stimulation applied to the innervation territory ofthe superficial peroneal nerve was used as a search strategy,
therefore ruling out a hypothetical ‘‘search bias’’ if natural stimuli
would have been used. One possibility for the lack of C-nocicep-
tor ‘‘profiles’’ would be that C-nociceptor axons were, in fact,
present but rendered unexcitable by the mutation; therefore,
we would have not been able to detect them with microneurog-
raphy. This hypothesis would be consistent with our findings in
iPSC nociceptors of hypoexcitability. An alternative explanation
would be that there is an anatomical lack of C-nociceptors,
which is a hypothesis that we explored with skin biopsy.
The dogma has been that small fibers are structurally normal in
CIP due to SCN9A mutations. The nerve biopsy in the original
SCN9A pedigree was normal (Cox et al., 2006). This is thought
to distinguish CIP due toSCN9Amutations fromCIP due to other
causes, for example, NGF mutations (Einarsdottir et al., 2004),
which result in severe developmental degeneration of nocicep-
tors. To our surprise, there were clear and marked reductions
in epidermal innervation of the distal leg in all three of the
SCN9A CIP participants. IENFD in these participants was well
below the fifth centile of normative data for age and gender.
Two previous case reports have also reported reduced IENFDNeuron 101, 905–919, March 6, 2019 913
Figure 7. NaV1.7 Selectivity of Clinical
Compounds
(A) Rheobase of HC1 and NaV1.7 KO neurons
treated with vehicle (0.01% DMSO) or varying
concentrations of the NaV1.7 blockers, BIIB074,
and PF-05089771. Number of recordings are de-
noted in the bars, Kruskal-Wallis followed by
Dunn’s multiple comparison test.
(B) Response of HC1 neurons to ramp depolari-
zation with and without drug treatment.
(C) Representative traces of action potential firing
in response to multiple depolarizing current pulses
given at 20 Hz. Red traces signify the action po-
tential generated in response to the 1st current
step.
(D) Quantification of action potential failures in
response to multiple depolarizing current pulses
given at 20 Hz following vehicle or drug treatment.
Number of recordings are denoted in the bars.
Kruskal-Wallis followed by Dunn’s multiple com-
parison test.
Results pooled from at least three independent
experiments and represent mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 HC1 treat-
ment versus vehicle control. #p < 0.05, ##p < 0.01,
####p < 0.0001 NaV1.7 KO treatment versus vehicle
control.when assessed at a distal site (Nilsen et al., 2009; Marchi
et al., 2018).
One explanation for the reduction of IENFD is the outcome of
previous injuries. We therefore also performed skin biopsies
from the thigh, a more proximal site with a higher innervation
density than the distal leg. Again, there was a virtual absence
of epidermal nerve fibers in the CIP patients. Dermal nerve fibers
could still be observed. The implication is that in humans, NaV1.7
is required for the long-term structural integrity of the distal ter-
minations of nociceptors. A recent case report describes a
young patient (2-year-old girl) with CIP due to SCN9Amutations,
in which IENFD was already severely reduced (Marchi et al.,
2018). The loss of IENFs in CIP could be due to a ‘‘dying-
back’’ in early life stages or disruption of normal C-nociceptor
development during embryogenesis, occurring as a result of
the loss of NaV1.7 function. Our studies in vitro failed to observe
an intrinsic defect in neurite outgrowth of iPSC nociceptors lack-
ing NaV1.7. However, appropriate epidermal targeting of endog-
enous nociceptive afferents requires complex environmental
and chemical cues and for axons to travel large distances
(Wang et al., 2013), which we cannot fully model in our culture
system. Therefore, we cannot rule out a role for loss of NaV1.7
in this context. The contribution of NaV1.7 to IENFD could be
due to afferent hypoexcitability (discussed below) or a non-ca-
nonical role for the ion channel.
Our human data contrast with findings in mice lacking NaV1.7,
in which epidermal innervation is normal (Gingras et al., 2014).
The reason for the loss of IENFs in humans, but not mice, is
not resolved; there could be differences in activity-dependent
maintenance of C-fiber terminals between the two species,
especially given the need to maintain longer axons in human.914 Neuron 101, 905–919, March 6, 2019The presence of a normal flare reaction despite complete anal-
gesia and virtually complete denervation of the epidermis is
intriguing. The flare response is neurally mediated following acti-
vation of cutaneous C-fibers, leading to axon reflex-mediated
release of neuropeptides onto the perforating arterioles of the
skin (Szolcsanyi et al., 1992; Meyer et al., 1985). If all C-fibers
had degenerated, then the flare response would be absent. Its
preservation suggests that at least some C-fiber terminals lack-
ing NaV1.7 within the dermis could still maintain short-range ac-
tion propagation (sufficient to induce neuropeptide release),
even if they were unable to continue such conduction to the
nerve trunk.
These in vivo findings predict that following application of
noxious stimuli to CIP patients, there will be a marked reduction
of nociceptor input from the periphery to the spinal cord and
subsequently to higher brain centers. In one participant, we un-
dertook fMRI using arterial spin labeling to test this hypothesis.
Using a previously published protocol (Segerdahl et al., 2015),
we applied the algogen, capsaicin, and warmth to the leg. This
did not elicit any pain in the CIP participant but was intensely
painful in control participants. Increased CBF was observed in
the primary somatosensory cortex, the dorsal anterior cingulate,
and the posterior cingulate in the CIP participant. However, in
healthy controls, a much more extensive cortical network
demonstrated significant increases in CBF that included primary
and secondary somatosensory cortices, dorsal lateral prefrontal
cortex, insula (anterior, mid, and posterior), anterior cingulate,
putamen, nucleus accumbens, periaqueductal gray, and the
cerebellum. The NPS is an fMRI-based measure that has been
shown to be predictive of pain intensity (Wager et al., 2013). A
comparison of the NPS response values showed that there
was no overlap between the NPS and brain activity from the CIP
participant in response to capsaicin-induced tonic heat hyperal-
gesia. By comparison, the strong NPS response in HCs reflects
that there was clear overlap with the NPS and pain-related brain
activity in these participants, and this was strongly related to an
intense pain experience; data that were confirmed by the pain re-
ports collected during these scans. One previous study did not
find a difference in BOLD fMRI responses within a priori-defined
regions of interest identified using Neurosynth (that does not
restrict regions to nociceptor-driven pain) when comparing CIP
patients with healthy controls (Salomons et al., 2016). However,
their approach has been criticized from a methodological and
interpretative perspective, limiting the conclusions to be drawn
(B€uchel et al., 2016). There are a number of key differences be-
tween the Solomons study and ours that limit direct comparison,
including the imaging method, pain modality, and analysis pipe-
line employed. Crucially, we used a tonic application of the algo-
gen capsaicin, which is well known to evokemoderate-to-severe
pain in healthy controls by selectively activating nociceptors and
is not confounded by co-activation of low-thresholdmechanore-
ceptors. Nonetheless, we conclude here that a lack of nocicep-
tor-driven pain in CIP does not result in the same activation
pattern as healthy controls and, as such, supports the peripheral
observations.
In order to better understand the impact of NaV1.7 mutations
on the excitability of sensory neurons, we used iPSC-derived no-
ciceptors combined with genome engineering. We first charac-
terized the expression and sub-cellular localization of NaV1.7 in
iPSC nociceptors. NaV1.7 was robustly expressed at the soma
membrane, along the length of the axon, andwas enriched in ter-
minal structures. In myelinated axons, the channel was appropri-
ately localized to nodes of Ranvier as previously reported in vivo
in rodent (Black et al., 2012).
Consistent with studies of rodent NaV1.7 KO DRGs (Raouf
et al., 2012), we observed reliable hypoexcitability in CIP iPSC
nociceptors, demonstrable by an increased current threshold
to activation and a reduction in action potential firing in response
to prolonged supra-threshold stimulation. These phenotypes
replicated in isogenic NaV1.7 KO iPSC nociceptors and rescued
in CIP iPSC nociceptors in which one deleterious SCN9A allele
was genome corrected to the wild-type sequence. Interestingly,
while firing thresholds were completely reversed to normal in our
genome-corrected iPSC nociceptors, firing in response to su-
pra-threshold stimuli was not. This may indicate that human no-
ciceptors require two functional copies of SCN9A to be fully
excitable.
The isogenic NaV1.7 KO iPSC nociceptors allowed us to
further interrogate the association between channel activity
and nociceptor function. In contrast to a recent report suggest-
ing a limited contribution of NaV1.7 to total NaV current in
human sensory neurons (Zhang et al., 2017), we found that the
channel provides 24% of peak total NaV current in our iPSC
nociceptors.
Zhang et al. (2017) failed to record TTX-sensitive low-threshold
rampcurrents in cadaveric humanDRG in vitro and hadmixed re-
sults when using selective toxins and blockers to assess the
contribution of NaV1.7 to total TTX-sensitive currents. Pro-Tx II
failed to inhibit putative TTX-s currents, while PF-05089771 re-sulted in complete inhibition. The authors postulate that either
Pro-Tx II loses potency or PF-05089771 loses selectivity when
used against NaV channels in their native environment rather
than heterologous expression systems where both have previ-
ously been shown to be potent and specific (Schmalhofer et al.,
2008; Alexandrou et al., 2016). Our datawould argue that, at least
in terms of functional outcome (i.e., firing properties), PF-
05089771 is selective for NaV1.7. This conclusion complements
our findings of consistent hypoexcitability in iPSC lines lacking
NaV1.7 function and leads us to conclude that the channel con-
tributes significantly to neuronal properties. At the level of tran-
scription, NaV1.7 is the most abundantly expressed NaV channel
in human DRG (Chang et al., 2018), and it would be surprising if
the channel did not play a significant role in sensory neuron phys-
iology. Dissociation and culture of cadaveric DRG and our iPSC
differentiation strategy offer two approaches to study human
sensory neuron biology. iPSC differentiation results in neurons
that share many transcriptional and functional characteristics of
in vivo nociceptors (Chambers et al., 2012; Young et al., 2014),
but it does not recapitulate thewhole panoply of sensory neurons
present in the DRG. Cadaveric DRG are becoming more avail-
able, but the study of very rare diseases, such as CIP, will remain
a challenge. Genetic modification of iPSCs allows the refined
interrogation of gene function, negating the confound of com-
pound selectivity inherent to pharmacological studies.
We have consistently found that iPSC nociceptors that lack
NaV1.7 (whether derived from CIP or NaV1.7 KO lines) were still
able to generate action potentials at the cell soma (albeit
requiring greater current stimuli). This finding is consistent with
computer simulation models and dynamic clamp recordings,
which describe a linear relationship between NaV1.7 conduc-
tance and the threshold for firing a single action potential, as
well as firing in response to supra-threshold depolarizing stimuli
(Choi and Waxman, 2011; Vasylyev et al., 2014). Crucially in
these studies, as in ours, nociceptors are capable of generating
action potentials at the cell soma in the complete absence of
NaV1.7 conductance.
Channel kinetics of NaV1.7 position it as an attractive candi-
date to amplify small depolarizing currents and tomediate action
potential electrogenesis at the peripheral terminal (Cummins
et al., 1998). We attempted to better model terminal generator
potentials in vitro by applying a graded supra-threshold stimuli
that slowly depolarized the membrane potential (Cheng et al.,
2011). NaV1.7 KO iPSC nociceptors were markedly less able to
respond than healthy control iPSC nociceptors, especially in
response to slower depolarizing stimuli. A necessary role for
NaV1.7 in initial generation and invasion of the action potential
in nociceptor terminals would be consistent with our in vivo mi-
croneurography findings. There are preclinical data that NaV1.7
may regulate neurotransmitter release from the central terminal
of nociceptors (Alexandrou et al., 2016; Minett et al., 2012).
This is certainly a plausible mechanism, although it is unlikely
tomake amajor contribution to lack of pain perception in the par-
ticipants with CIP that we report here, given the lack of functional
nociceptor axons within peripheral nerve, such that the deficit in
nociceptive transmission is proximal to the central terminal.
We took advantage of our NaV1.7 KO to probe pharmacology.
Although endogenous opioids have been suggested to beNeuron 101, 905–919, March 6, 2019 915
upregulated in the absence of functional NaV1.7 and to contribute
to the CIP phenotype (Minett et al., 2015), we did not see upre-
gulation of PENK mRNA in NaV1.7 KO iPSC nociceptors or
meaningful expression to begin with in healthy control neurons.
In support of this finding, the marked hypoexcitability in NaV1.7
KO iPSC nociceptors that we observed was independent of
endogenous opioid signaling. These results in isolated iPSC no-
ciceptors, however, cannot rule out a role for central opioid
mechanisms contributing to analgesia in the absence of
Nav1.7. We utilized our NaV1.7 KO lines to test the specificity of
NaV1.7 selective small molecules in clinical development. PF-
05089771 is a NaV1.7-selective arylsulfonamide that has under-
gone phase II trials for primary erthromyelgia (Cao et al., 2016)
and painful diabetic neuropathy (McDonnell et al., 2018). Treat-
ment of healthy control iPSC nociceptors with PF-05089771
decreased excitability, whereas it had no effect on NaV1.7 KO
neurons, suggestive of good specificity. BII074 has successfully
undergone phase II trials for trigeminal neuralgia (Zakrzewska
et al., 2017). We found NaV1.7-independent effects present at
clinically relevant concentrations that enhanced steeply as
dose increased. In particular, use-dependent block of nociceptor
firing by BII074 appeared to be largely independent of NaV1.7.
Thismay be particularly relevant for trigeminal neuralgia, in which
there are paroxysms of pain. This drug was well tolerated in the
phase II trial (Zakrzewska et al., 2017); however, our resultswould
caution against seeking to increasedosage toenhance therapeu-
tic outcomes due to the risk of off-target effects.
To summarize, we have undertaken a detailed assessment of
the clinical phenotype of CIP due to SCN9Amutations as well as
investigating the impact of these mutations on both cellular
models and the somatosensory nervous system in vivo. The sen-
sory impairments due to loss of NaV1.7 do not only relate to pain,
but subjects also demonstrate deficits in temperature discrimi-
nation and itch. NaV1.7 is expressed by human iPSC nocicep-
tors, is trafficked to the cell surface, axon, and terminals, and
has a key role in the regulation of excitability especially in
response to slow-graded depolarizing stimuli. Reassuringly,
recently developed NaV1.7 blockers tested in these cellular
models were able to alter somal excitability to levels similar to
that of NaV1.7 KO, with a caveat that in some cases these drugs
lacked specificity for NaV1.7. Finally, in humans with bi-allelic
SCN9Amutations, we have found a profound loss of nociceptors
in vivo defined both structurally and functionally. This likely re-
flects the long-term loss of NaV1.7 and may suggest that acute
pharmacological inhibition of NaV1.7 in humans may not fully
replicate the CIP phenotype.STAR+METHODS
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Antibodies
Rabbit anti-Brn3a Millipore Cat# AB5945; RRID: AB_92154
Chicken anti-NF200 Abcam Cat# ab4680; RRID: AB_304560
Rabbit anti-HA Cell Signaling Technology Cat# 3724; RRID: AB_1549585
Mouse anti-HA Sigma-Aldrich Cat# A2095; RRID: AB_257974
Mouse anti-Beta-Actin Sigma-Aldrich Cat# A5316; RRID: AB_476743
Rat anti-MBP Abcam Cat# ab7349; RRID: AB_305869
Phalloidin-Tetramethylrhodamine B
isothiocyanate (TRITC)
Sigma-Aldrich Cat: P1951; RRID: AB_231514
Rabbit anti-Protein Gene Protein 9.5 (PGP 9.5) Zytomed Cat# 516-3340
Amersham ECL Mouse IgG, HRP-linked
whole antibody (from sheep)
GE Healthcare Life Sciences Cat# NA931V; RRID: AB_772210
Amersham ECL Rabbit IgG, HRP-linked
whole antibody (from donkey)
GE Healthcare Life Sciences Cat# NA934V; RRID: AB_772206
Donkey anti-rabbit IgG Alexa 488 Thermo Fisher Scientific Cat# A-21206; RRID: AB_2535792
Donkey anti-rabbit IgG Cy3 Jackson ImmunoResearch
Labs
Cat# 711-166-152; RRID: AB_2313568
Donkey anti-mouse IgG Alexa 488 Thermo Fisher Scientific Cat# A-21202; RRID: AB_141607
Goat anti-chicken Alexa 488 Thermo Fisher Scientific Cat# A-11039; RRID: AB_2534096
Donkey anti-rabbit IgG Alexa 546 Thermo Fisher Scientific Cat# A10040; RRID: AB_2534016
Goat anti-rabbit IgG Alexa 488 Thermo Fisher Scientific Cat# A-11008; RRID: AB_143165
Guinea pig anti-CASPR Gift from Bhat MA N/A
Mouse anti-S100 Sigma-Aldrich Cat#S2532; RRID: AB_477499
Goat anti-Rat CF405M Sigma-Aldrich Cat#SAB4600463
Biotinylated Goat anti-rabbit Vector Biolabs Cat# BA-1000; RRID: AB_2313606
Alexa Fluor 488 streptavidin Thermo Fisher Scientific Cat#S11223; RRID: AB_2336881
Bacterial and Virus Strains
Lentivirus CAMKII-EGFP Signagen Cat#: SL100304
Chemicals, Peptides, and Recombinant Proteins
BDNF recombinant human Thermo Fisher Scientific Cat#10908010
NT3 recombinant human Peprotech Cat#450-03
b-NGF recombinant human Peprotech Cat#450-01
GDNF recombinant human Peprotech Cat#450-10
Cultrex Mouse Laminin I, Pathclear R&D Systems Cat#3401-010-02
CHIR99021 Sigma-Aldrich Cat#SML1046
SU-5402 Sigma-Aldrich Cat#SML044
DAPT Sigma-Aldrich Cat#D5942
LDN-193189 Sigma-Aldrich Cat#SML0559
SB431542 Sigma-Aldrich Cat#616461
PF-05089771 Sigma-Aldrich Cat#PZ0311
BIIB074 Axon Medchem Cat#2548
Naloxone Sigma-Aldrich Cat#N7758
Critical Commercial Assays
Pierce BCA Protein Assay Kit Thermo Fisher Scientific Cat#: 23227
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Deposited Data
Human iPSC (AD2, AD3, NHDF, AH017) and
iPSC-nociceptor RNA-seq data
Baskozos et al., 2019 GEO: GSE107181
Human DRG L2 RNA-seq data Ray et al., 2018 dbGAP: phs001158.v1.p1
Single cell RNA-seq human iPSC and
iPSC-nociceptor data
Schwartzentruber et al., 2018 ENA: ERP020576
Human whole blood, skin, skeletal muscle,
fibroblasts, and tibial nerve raw counts
GTEx V7 N/A
Experimental Models: Cell Lines
Human iPSC line_ HC1 StemBANCC Consortium AD2-1
Human iPSC line_ HC2 StemBANCC Consortium NHDF-1
Human iPSC line_HC3 StemBANCC Consortium AH017-7
Human iPSC line_CIP1.1 StemBANCC Consortium 811-05-01
Human iPSC line_CIP1.2 StemBANCC Consortium 811-05-03
Human iPSC line_CIP2 StemBANCC Consortium 246-03-01
Oligonucleotides
YWHAZ F 50-CCTGCATGAAGTCTGTAACTGAG-30 IDT N/A
YWHAZ R 50-GACCTACGGGCTCCTACAACA-30 IDT N/A
SCN9A F 50-GGCATAGGCGAGCACATGAA-30 IDT N/A
SCN9A R 50-AACAAGGAGCCACGAATGCT-30 IDT N/A
Recombinant DNA
pSpCas9(BB)-2A-Puro (PX459) V2.0 Addgene (Depositor:Feng
Zhang)
#62988
Software and Algorithms
ImageJ/Fiji NIH https://imagej.nih.gov/ij/index.html, https://fiji.sc/
Clampfit 10 Molecular Devices http://mdc.custhelp.com/app/answers/detail/
a_id/18779/?/axon%E2%84%A2-
pclamp%E2%84%A2-10-electrophysiology-
data-acquisition-%26-analysis-software
Prism 7.0 GraphPad software https://www.graphpad.com/
FMRIB’s Software Library Smith et al., 2004 https://fsl.fmrib.ox.ac.uk/fsl/fslwiki
QTRAC software Institute of Neurology,
London, UK
N/A
STAR version 2.5.2b Dobin et al., 2013 https://github.com/alexdobin/STAR
HTSeq version 0.11.0 Anders et al., 2015 https://github.com/simon-anders/htseq
DESeq2 version 1.18.1 Love et al., 2014 https://www.bioconductor.org/packages/
release/bioc/html/DESeq2.html
GTEx portal version 7 Carithers and Moore, 2015 https://gtexportal.org/home/
R version 3.4.4 R Development Core
Team, 2018
https://cran.r-project.org/
Ggplot2 version 2.2.1 Wickham, 2009 https://cran.r-project.org/web/packages/
ggplot2/index.html
IN Cell Developer Toolbox analysis software build 1.9.2 GE IN Cell Developer Toolbox analysis
software build 1.9.2CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Professor
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethics
The three study participants (31 year old male, 34 year old male and 44 year old female) signed written consent as part of the Painful
Channelopathies Study, approved by Riverside research ethics committee (NRES reference: 12/LO/0017).
Generation and Culture of hiPSC Lines
Healthy control iPSCs were derived from fibroblasts as described in Clark et al. (2017). AD2 (termed HC1 throughout the study)
from 51 year old male, was reprogrammed by non-integrating Sendai viral vectors using the CytoTune-iPS Reprogramming Kit
(ThermoFisher). NHDF (termed HC2 throughout the study) from 44-year-old female, was reprogrammed with retroviral vectors
(Addgene: 17220: pMXs-hc-MYC, 17219: pMXs-hKLF4, 17218: pMXs-hSOX2, 17217: pMXs-hOCT3/4, 13354: pMXs-Nanog).
AH017-7 (termed HC3 throughout the study) from 67-year-old female, was reprogrammed using the tetracistronic Sendai virus vec-
tor SeVdp(KOSM)302L. CIP iPSC patient lines were obtained through the IMI/EU sponsored StemBANCC consortium via the Human
Biomaterials Resource Centre, University of Birmingham, UK (https://www.birmingham.ac.uk/facilities/hbrc). Fibroblasts from CIP 1
(31-year-old male) and CIP 2 (34-year-old male) were reprogrammed using the CytoTune-iPS Reprogramming Kit (ThermoFisher) to
generate two clones fromCIP 1 (cCIP1.1, and cCIP1.2) and one fromCIP 2 (cCIP2). All iPSC lines were subject to strict quality control
checks before initiation of differentiation and following genome editing. This included CytoSNP analysis (Illumina CytoSNP-12-v2.0
array) and pluripotency characterization. All cells were karyotypically normal and negative for mycoplasma. iPSC were maintained in
mTesR1 (StemCell Technologies) on Matrigel (Corning) coated dishes. Cells were routinely passaged at 80% confluence with either
Versene EDTA or Accutase treatment (Life Technologies). In the event single cells were required re-plating, medium was supple-
mented with Y-27632 (Tocris).
Differentiation of iPSCs
iPSCs were differentiated following a previously published protocol (Chambers et al., 2012) with modifications. In brief, cells were
passaged using Versene EDTA (ThermoFisher) and plated at high density. Neural induction commenced with the addition of
SMAD inhibitors SB431542 (Sigma, 10 mM) and LDN-193189 (Sigma, 100 nM) to KSR base medium (Knockout-DMEM, 15%
knockout-serum replacement, 1% Glutamax, 1% nonessential amino acids, 100 mM b-mercaptoethanol, (ThermoFisher)). Three
additional small molecules were introduced on day 3 (CHIR99021 (Sigma, 3 mM), SU5402 (R&D Systems, 10 mM) and DAPT (Sigma,
10 mM). The dual SMAD inhibitors were withdrawn on day 5. The basemediumwas gradually transitioned to N2/B27medium (Neuro-
basal medium, 2%B27 supplement, 1%N2 supplement, 1%Glutamax, (ThermoFisher)) in 25% increments. Cells were replated onto
glass coverslips at day 12 of the differentiation in N2/B27 medium supplemented with four recombinant growth factors at 25ng/ml
(BDNF; ThermoFisher, NT3, NGF, GDNF; Peprotech). CHIR90221 was included for 4 further days. Laminin (Cultrex Mouse Laminin I,
R&D systems, 500ng/ml) was included in long-term maintenance medium from 25 days onward. Medium changes were performed
twice weekly.
METHOD DETAILS
Neurological assessment
Each study participant underwent a comprehensive structured neurological examination. A detailed upper and lower limb neurolog-
ical examination was performed to detect clinical signs of a peripheral neuropathy (O’Brien, 2010). Orthostatic hypotension was as-
sessed by measuring lying and standing blood pressure and was defined as either a 20 mm Hg reduction in systolic or a 10 mm Hg
reduction in diastolic blood pressure within 3 min of standing.
Nerve conduction tests
Nerve conduction tests were performed with an ADVANCE system (Neurometrix, Massachusetts, USA) and used conventional reus-
able electrodes. Sensory nerve conduction studies were recorded from the sural, superficial peroneal, median and ulnar nerves. Mo-
tor nerve conduction studies were recorded from the peroneal, tibial, median, and ulnar nerves. Theminimum case definition criterion
for electrodiagnostic confirmation of peripheral neuropathy was an abnormality of any attribute of nerve conduction in two separate
nerves, one of whichwas the sural nerve (Buschbacher andOrahlow, 2006). Variables such as skin temperature, age, height, sex, and
weight were measured and accounted for when interpreting nerve conduction tests. Our protocol was in line with those recommen-
ded by the American Academy of Neurology and American Association of Electrodiagnostic Medicine. Nerve conduction tests were
not repeated if study participant had previous results.
Nerve excitability testing
Sensory nerve excitability measurements were performed using automated QTRAC software (TRONDNF, QTRAC, Institute of
Neurology, London, UK). This protocol was designed for the rapid acquisition of multiple excitability parameters (Kiernan et al.,
2000). Sensory nerve action potentials were recorded from the index finger using surface electrodes after stimulation of the median
nerve at thewrist. Skin temperature wasmonitored near the site of stimulation andmaintained above 32C for each study. Each nervee3 Neuron 101, 905–919.e1–e8, March 6, 2019
excitability recording consists of four tests that include stimulus–response behavior, threshold electrotonus, the recovery cycle and
the current–threshold relationship (Kiernan et al., 2000). Nerve excitability measurements provide indirect information about the be-
haviors of voltage-gated sodium channels, potassium channels, energy-dependent pumps and exchangers that are activated during
the process of action potential generation and impulse transmission (Krishnan et al., 2009).
Intra-epidermal nerve fiber assessment
The determination of intra-epidermal nerve fiber density (IENFD) from skin biopsy samples is a validated and sensitive diagnostic tool
for the assessment of small fiber pathology. Biopsy samples were taken in accordance with the consensus document produced by
the European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the utilization of skin biopsy samples in the
diagnosis of peripheral neuropathies (Lauria et al., 2010). Skin biopsies were taken with a disposable 3mm punch biopsy circular
blade (Stiefel Laboratories Inc, GSKPlc) from 10 cmproximal to the lateral malleolus and from the lateral aspect of the proximal thigh.
Nerve fibers were visualized using rabbit anti-PGP9.5 antibody (Zytomed, 1:200) with Cy3-conjugated donkey anti-rabbit IgG (Jack-
son ImmunoResearch, 711-165-152, 1:1000). The nerve fibers are counted as they cross the epidermal-dermal junction in order to
quantify intra-epidermal nerve fiber density. Images were taken using an LSM 700 microscope with a Plan-Apochromat objective
(Carl Zeiss) at 40 3 and 63 3 magnification.
Quantitative sensory testing (QST)
Somatosensory phenotype was determined using a published protocol of the German research network of neuropathic pain (DFNS)
(Rolke et al., 2006). Cold and warm detection thresholds, as well as cold and heat pain thresholds and thermal sensory limen
(including paradoxical heat sensations), were established using a Thermotest (Somedic, Ho¨rby, Sweden). We also testedmechanical
detection and pain thresholds as well as mechanical pain sensitivity, allodynia, pressure pain thresholds, wind up ratio and vibration
detection thresholds. Participants were familiarized with the testing procedure on the dorsum of the forearm before all parameters
were measured over the dorsum of hand and foot. Pressure pain thresholds were recorded over the thenar eminence and arch of the
foot. Vibration detection thresholds were tested over the ulnar styloid and medial malleolus.
QST data were entered into the data analysis system Equista provided by the DFNS. Equsita transformed the raw QST data into
z-scores thus normalizing for age, gender, and body location of testing (Magerl et al., 2010). Positive z-scores denote gain of function
whereas negative z-scores denote loss of function. We had previously generated z-scores for QST measures included in the DFNS
protocol for participant CIP1 (Ramirez et al., 2014). These have been replotted using the latest version of Equista in order to generate
z-scores which are comparable between the three participants.
Chemical algogens
We applied 30% mustard oil (Allyl isothiocyanate dissolved in olive oil, Sigma) to the volar surface of the forearm at a midpoint be-
tween the wrist and elbow. We iontophoresed 2% histamine (0.02 g in 100ml 0.9% NaCl, Sigma) into the skin of the volar surface of
the forearm at a midpoint between the wrist and elbow, at 1.2mA for 20 s.
Microneurographic recordings
Microneurography (Vallbo and Hagbarth, 1968) was used to record action potentials of C-fibers from the lateral branch of the super-
ficial peroneal nerve at the dorsum of the left foot. The subjects sat relaxed on a recliner, with the legs supported on a padded plat-
form. Intraneural recordings were obtained using a 1MU impedance, 200mm-diameter lacquer-insulated tungsten microelectrode
(FHC, USA), which was inserted percutaneously into the nerve. An uninsulated tungsten reference electrode was inserted into
the skin 1 to 2 cm outside the nerve trunk. Neural signals were amplified by an isolated high-input impedance differential amplifier
(NeuroAmpEx; ADInstruments, Australia) and filtered with an adjustable analog filter (gain 10,000; band-pass 100-2,000Hz). To
improve the recorded signal quality, 50Hz mains line interference was removed with an on-line noise eliminator (Hum Bug, Quest
Scientific, Canada). The recorded and amplified nerve signal was digitized (NI DAQCARD-6062E; National Instruments Europe
Corp., Debrecen, Hungary) at a sampling rate of 20 kHz. Further digital filtering (band-pass 300–2,000 Hz) and clamping of the base-
line were performed both on-line and during offline analysis for a better visualization of the action potentials. Skin temperature was
recorded continuously with an infrared thermometer (PCE-IR10, PCE Iberica, Spain) pointing to the skin adjacent to the receptive
fields of the units under study. Responses were recorded and analyzed with QTRAC software (Institute of Neurology,
London, UK), specially modified to track peak latencies and display them as a raster plot. In the latency raster plots, each peak in
the filtered voltage signal that exceeded a specified level is represented by a dot on a plot with latency as the ordinate and elapsed
time as the abscissa (see Serra et al., 1999). Depending on the level chosen, the dots could represent action potentials or noise. An
isolated constant-current stimulator (DS7; Digitimer Ltd, UK) was used for stimulation (rectangular pulses, 300ms duration) of the
cutaneous receptive fields with a pair of needle stainless steel electrodes resting on the surface of the skin. Only fibers with latencies
compatible with conduction velocities in the C-fiber range (< 2 m/s) were studied. A combination of 0.25-Hz baseline stimulation and
a 3-min 2-Hz train were given to induce activity-dependant slowing (ADS) of conduction velocity. Profiles of ADSwere used to classify
the recorded C-fibers into C-nociceptors, C-thermoreceptors, low threshold C-mechanoreceptors or sympathetic efferents
following pre-established criteria (Serra et al., 1999, 2004; Campero et al., 2001, 2004).Neuron 101, 905–919.e1–e8, March 6, 2019 e4
fMRI
The CIP participant (CIP 2) was scanned on two visits (1 week apart) using a 3T Siemens scanner fitted with a 32-channel head and
body coil. Each scan visit was 2 h. T1-weighted structural images were acquired with a 3DMPRAGE sequence (13 1 x 1mm voxels).
Absolute cerebral blood flow (CBF) data were acquired using amulti-inversion time pseudo-continuous arterial spin labeling (pCASL)
sequence described previously (Segerdahl et al., 2015). Briefly, ‘tag’ and ‘control’ images were acquired sequentially every repetition
time (TR = 4 s) with a label duration of 1.4 s. A total of six inversion times were used. B0 shimming was employed to mitigate off-reso-
nance artifacts within the imaging region and labeling plane. A total of 96 volumes were analyzed for each experimental condition.
The participant was scanned during four different conditions: rest (no stimulation), tonic thermal stimulation (T = 40.3C), tonic
capsaicin, and the tonic thermal stimulation applied to the capsaicin-treated skin (‘‘thermal + capsaicin’’). Stimulations were applied
to the antero-medial aspect of the lower right forearm. The capsaicin scans did not commence until the participant’s skin was treated
with the cream for 25 min. This period was found previously to capture of the onset of 1% capsaicin-induced heat pain (Segerdahl
et al., 2015). Three 5-min runs of each condition were scanned in each session (Figure 4B). Verbal intensity ratings (using an 11-point
numerical rating scale) were collected at the start and end of each scan run. For comparison, data collected from twelve healthy con-
trol participants (HC) experiencing a similar topical capsaicin cream paradigm (Segerdahl et al., 2015) were included in our analysis
pipeline for comparison with the CIP participant data. Here, each healthy control participant was scanned once. During this scan, a
single trial testing the effects of each experimental condition once was observed for that subject. Multiple-repeat trials were not
completed on the HC cohort.
All data were analyzed using FMRIB’s Software Library (FSL) (Smith et al., 2004). The FMRI analysis was completed in each
subject’s native anatomical space and then was co-registered to a standard MNI152 template brain using non-linear registration
(FNIRT). ASL functional data were pre-processed using previously published methods that adhere to current guidelines (Alsop
et al., 2015; Okell et al., 2013; Segerdahl et al., 2015). The absolute CBF time series generated for each subject during each condition
was averaged using a mixed effects model (to account for voxel-wise variance of the Bayesian fit during CBF quantification). This
generated a whole brain voxel-wise absolute CBF volume with a corresponding variance image for each scan run at each condition
to use in FEAT. A total of six runs (i.e., 3 scan runs X 2 scan sessions) were collected from the CIP patient for each condition. The
whole brain absolute CBF volumes were then inputted into a repeated-measures design in FEAT to determine the average change
in perfusion for each condition compared to rest (Mixed Effects; z > 3.1, p < 0.05) (Figure 4C).
Additionally, we used the Neurological Pain Signature (NPS) to test whether the perfusion changes observed during the capsaicin-
evoked thermal condition were overlapping anatomically with this physical pain signature thereby confirming this was a distinct
perceptual experience in CIP versus HC. The ‘‘thermal+capsaicin > rest’’ condition was selected because it was themaximally salient
condition experienced by both groups (albeit a non-painful one for CIP) (Figure 4A) and it was the only contrast to yield a statistically
significant change in perfusion in CIP (Figure 4C). To do this we applied the NPS to the subject-level cope images representing the
contrast between the ‘‘thermal + capsaicin’’ and ‘‘rest’’ conditions using the CanLab Toolbox (Wager et al., 2013). Briefly, the NPS is a
multivariate pattern of brain activity that is both sensitive and specific for classifying phasic and acute experimental physical pain
from non-painful stimuli and can be used as a proxy for measuring heat pain intensity (Wager et al., 2013). The NPS was calculated
for each cope image by taking the dot product of it and the NPS. The mean scalar NPS values for both CIP (i.e., mean across six
repeat trials) and HC (mean across the group) are plotted in (Figure 4D).
Plasmids and site-directed mutagenesis
Human NaV1.7 cDNA was cloned into a modified pcDNA3 expression vector containing downstream IRES and dsRED2 sequences
(SCN9A-IRES-DsRED) (Cox et al., 2006). Human b1 and b2 subunits were cloned into pIRES2-AcGFP (SCN1B-IRES-SCN2B-IRES-
eGFP) (Cox et al., 2006). Mutations were introduced using QuikChange II XL site-directed mutagenesis kit (Agilent).
CRISPR-Cas9 genome editing
Streptococcus pyogenes Cas9 target sites were identified using the online CRISPR design tool (https://crispr.mit.edu) or ChopChop
(http://chopchop.cbu.uib.no/). Two to three guides were selected per location and in vitro cuttingwas assessed usingHEK293T cells.
Finalised gRNAs were selected based on strength of T7E1 assay (New England Biolabs) and proximity to the desired editing loci.
iPSCs were dissociated with Accutase, resuspended in mTesR1 supplemented with Y-27632 (Tocris). Dissociated cells were then
immediately transfected with 6 mg of PX459 pSpCas9(BB)-2A-Puro V2.0 (Addgene) and 2 mg of phosphorothioate-treated ssODN
(Integrated DNA Technologies) using LT-1 (Mirusbio) reagent. Puromycin (0.3 mg/ml to 0.35 mg/ml) (ThermoFisher) was added to
the cells 18 h post-transfection for 48-72 h. Following selection, cells were plated at limiting densities for single clone isolation. Iso-
lated iPSC colonies were manually dissected and picked using a 21G needle; selected colonies were then expanded for DNA anal-
ysis. Clones were initially screened using diagnostic restriction digest or via PCR specific primers. Positive clones were subsequently
confirmed using Sanger sequencing.
Western blot
SCN9A-HA cells were grown under described iPSC culture conditions. Cells were lysed with ice cold modified RIPA (Sigma) supple-
mented with protease inhibitor cocktail (cOmplete Mini, EDTA-free, Roche) and lysates were cleared by centrifugation. Total protein
(10 mg) was incubated at 35C for 5 min with 5X Lamelli Buffer (ThermoFisher). Proteins were separated on 4%–12% BIS-TRIS minie5 Neuron 101, 905–919.e1–e8, March 6, 2019
gels (ThermoFisher) and transferred to a nitrocellulose membrane using BIORAD Trans-blot wet transfer system. Membranes were
blocked for 1 h in 8% skimmed milk, 0.1% PBS-T and incubated overnight with Anti-HA (1:1000, Cell Signaling Technology) and
b-actin (1:10,000, Sigma) in blocking solution. Membranes were washed 3X in 0.1% PBS-T, then incubated at room temperature
for 45 min with a HRP conjugated secondary antibody 1:10,000 (Amersham, G.E healthcare). Signal was detected with ECL Prime
using chemiluminescent detection film (G.E. healthcare).
Schwann cell co-cultures
Schwann cell co-cultures were prepared as previously described (Clark et al., 2017). In brief, 30,000 rat Schwann cells were added to
30 DIV iPSC-derived nociceptors in Schwann cell basal medium [DMEM/F12 (ThermoFisher), 5 mg/ml insulin (Sigma), 100 mg/ml
transferrin (Millipore), 25 ng/ml recombinant-human NGF (Peprotech), 25 ng/ml Selenium (Sigma), 25 ng/ml thyroxine (Sigma),
30 ng/ml progesterone (Sigma), 25 ng/ml triiodothyronine (Sigma) and 8 mg/ml putrescine (Sigma)]. Cells were either maintained
in this medium where ‘non-myelinating’ conditions were required, or myelination was induced one week after Schwann cell
addition by exposing the cells to myelination medium ((N2 medium, 1:300 phenol-free Matrigel (Corning), 5% charcoal-stripped
FBS (ThermoFisher), 25 ng/ml recombinant- human NGF (Peprotech), 50mg/ml ascorbic acid (Sigma)). Myelinating co-cultures
were maintained for a further 5 weeks before fixation for ICC analysis.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde (GIBCO) for 12 min and permeabilized with 0.1% Triton X-100 for 5 min. They were then
blocked with 5% normal donkey or goat serum (Sigma) for 30 min and incubated with primary antibodies overnight at 4C. The
following primary antibodies were used: Mouse anti-HA 1:400 (Sigma), Rabbit anti-HA (1:800), Chicken anti-NF200 (1:10,000), Rat
anti-MBP 1:400 (Abcam), Rabbit anti-Brn3a 1:500 (Millipore), Phalloidin-TRITC conjugate 1:150 (Sigma). Cells were washed 3X
with 0.1% PBS-TX before the species appropriate Alexa Fluorophore secondary antibodies were applied (all 1:1000). Coverslips
were mounted with VECTASHIELD Antifade Mounting Medium (Vector Laboratories). Immunostaining was visualized using a
confocal microscope (Zeiss LSM 700) and images were acquired using the Zen Black software.
Neurite outgrowth assays
For long-term axonal outgrowth, neurites and cell bodies of mature iPSC-nociceptors were visualized by immunocytochemistry
staining for NF200. 49 fields of view of a 12mm coverslip were acquired using GE IN Cell Analyzer 6000 build 6.1 at x10 objective.
Neuronal cell bodies in mature cultures cluster, making accurate determination of cell number challenging; axonal coverage was
therefore normalized to somal area (mm2) following confirmation of no significant difference between cell diameter of each group. Ac-
quired images were imported into an IN Cell Developer Toolbox analysis software build 1.9.2 and analysis was performed automat-
ically using a custom pipeline. In brief, a soma mask and total area network mask (neuronal somas and axons) were created from
binary images. The soma mask was subtracted from the network to yield axonal area. Fields containing artifacts e.g., tears in axons
or large debris, were manually excluded by eye. To compare fields of similar neuronal density, fields with a soma area between
1.5x104 mm2 and 4.5x104 mm2 (equivalent to 8.5%–25% area) were used for analysis. A minimum of 9 coverslips from each group
were analyzed.
For outgrowth following dissociation, mature iPSC-nociceptors were enzymatically treated with 30 min 0.1% TrypleE
(ThermoFisher), followed by mechanical dissociation with a fire polished glass pipette. Single cells were re-plated onto matrigel
treated coverslips at low density before fixation, immunocytochemistry, and analysis 12 h later. The proportion of neurons with
none, short (longest neurite < 3x soma diameter) or long neurites (longest neurite > 3x soma diameter) were scored manually. For
neurite length, images were acquired and neurites were semi-automatically traced and measured using the ImageJ plugin- Simple
Neurite Tracer (Longair et al., 2011). All experiments were performed by an experimenter blind to groups.
RNA extraction and cDNA synthesis
Total RNA extraction was performed using Tripure and High Pure RNA Isolation Kit (Roche). An on-column DNase digestion step was
included to eliminate contaminating gDNA. RNA was eluted in nuclease free ddh20. Synthesis of cDNA was performed using
EvoScript Universal cDNA Master (Roche).
RT-qPCR
RT-qPCR was performed using SYBRgreen qPCR master mix (Roche) according to the manufacturer’s instructions. Samples were
prepared in triplicate in 384-well reaction plates then run on LC480 II System (Roche). Primers were designed using Primer-BLAST
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer efficiency and specificity were validated before experimental use. Gene
expression for each target primer was normalized against the reference gene YWHAZ using the DDCT method.
RNA-sequencing
Analysis of sequencing data was processed in a workflow similar to previously (Baskozos et al., 2019). Publicly available RNA-seq
data were mapped in GRC.h.38 Human Genome using the STAR aligner with the ENCODE standard options. Read counts were
calculated at the gene level using HTSeq and the ENSEMBL gene set annotation GRC.h.38.88. Raw counts were normalized usingNeuron 101, 905–919.e1–e8, March 6, 2019 e6
the effective library size and transformed using the variance stabilizing transformation (VST) in R using DESeq2. Principal component
analysis (PCA) plots were generated from 100 randomly selected samples per GTEx human tissue, the human iPSC and iPSC-no-
ciceptor, the single-cell Human iPSC and iPSC-nociceptor and the human DRG RNA-seq data.
The top 500 ENSEMBL genes ranked by the standard deviation of their VST counts were selected for PCA. Data were centered and
scaled before PCA and samples are projected to standardized components. Ellipses represent the 95%CI of a tissue’s gene expres-
sion distribution. Distances between samples in the plot are proportional to Mahalanobis distance, i.e standard deviations from a
distribution’s mean.
Electrophysiology of HEK293T cells
Human embryonic kidney HEK293T cells were grown in a Dulbecco’s modified Eagle’s culture medium (DMEM/F-12, Invitrogen)
containing 10% fetal bovine serum and maintained under standard conditions at 37C in a humidified atmosphere containing 5%
CO2. Cells were transfected using the jetPEI transfection reagent (Polyplus-transfection Inc.) with either wild-type or
mutant NaV1.7 channel combined with b1 and b2 subunits (40:1 ratio). Recordings were made 48 to 72 h after transfection.
Whole-cell voltage clamp experiments were performed on transfected HEK293T cells exhibiting both red and green fluorescence
in the expectation that such cells would also express NaV1.7, combined with b1 and b2 subunits. All the recordings were conducted
at room temperature using an Axopatch 200B Amplifier, the Digidata 1550B LowNoise Data Acquisition System and the pClamp10.6
software (Molecular Devices). Data were filtered at 5kHz and digitized at 20kHz. Capacity transients were cancelled and series resis-
tance compensated at 70%–90% in all experiments. The extracellular solutions contained (inmM): 140NaCl, 3 KCl, 1 CaCl2, 1MgCl2,
10 HEPES, pH 7.3 with NaOH (adjusted to 320 mOsm/L with glucose). Patch pipettes were filled with an internal solution containing
(in mM) 140 CsF, 10 NaCl, 1 EGTA, 10 HEPES, pH 7.3 with CsOH (adjusted to 310mOsm/L with glucose) and had a typical resistance
of 2-3MU.
Electrophysiology of iPSC nociceptors
iPSC nociceptors were assessed for their biophysical properties 50-70 days following addition of growth factors. At this time point,
neurons exhibit mature electrophysiological properties (Weir et al., 2017), gene expression changes have plateaued (Young et al.,
2014), and high levels of NaV1.7 are expressed at the membrane (Figure 5E) Whole-cell patch clamp recordings using an Axopatch
200B amplifier and Digidata 1550 acquisition system (Molecular Devices) were performed at room temperature (22C). Data were
low-pass filtered at 2 kHz and sampled at 10 kHz. Series resistance was compensated 60%–80% to reduce voltage errors. All
data were analyzed by Clampfit 10 software (Molecular Devices)
Current clamp
Filamental borosilicate glass capillaries (1.5 mmOD, 0.84 mm ID; World Precision Instruments) were pulled to form patch pipettes of
3–5MU tip resistance and filled with internal solution containing (mM): 130 KCl, 1MgCl2, 5MgATP, 10 HEPES, and 0.5 EGTA; pHwas
adjusted to 7.3 with KOH and osmolarity set to 305 mOsm. Extracellular solution was perfused at a continuous rate of 1ml/min and
contained (mM): 140NaCl, 3 KCl, 2MgCl2, 2 CaCl2, 10HEPES and 10 glucose; pHwas adjusted to 7.3 with NaOH and osmolarity was
set to 315 mOsm. Resting membrane potential was assessed in bridge mode, while firing properties were assessed in current clamp
mode. Input resistance (RInput) was derived from the membrane potential deflection caused by a 20 pA hyperpolarising current pulse
at60mV. Cells were depolarised from a holding potential of60mV by current steps (50ms) of increasingmagnitude (D10 pA) until
an action potential was generated, to determine rheobase. Repetitive firing was evoked by prolonged (500ms) depolarising steps of
increasing increments (D25 pA). Depolarisation current ramps of 1nA amplitude were given over 100-1000ms to assess firing in
response to slow depolarisation. The ability of neurons to fire at high frequency was assessed by seventeen current stimuli of
1.5x rheobase (50ms) given at 20Hz.
Voltage clamp
To assess voltage-gated Na+ currents, patch pipettes of 1.5-3 MU were filled with an internal solution containing (mM): 140 CsF,
10 NaCl, 1 EGTA and 10 HEPES; pH was adjusted to 7.3 with CsOH and osmolarity set to 305 mOsm. The extracellular solution con-
tained (mM): 70 NaCl, 50 N-methyl-d-glucamine, 20 Tetraethylammonium chloride, 1 CaCl2, 3 KCl, 1 MgCl2, 10 HEPES, 10 Glucose
and 0.1 CdCl2; pH was adjusted to 7.3 with NaOH and osmolarity set to 305 mOsm. To assess voltage-gated Na
+ currents, mem-
brane potential was stepped from 80mV to +40mV in 10mV increments, from a holding potential of 100 mV. Intersweep intervals
were 10 s. To mitigate inconsistencies associated with space clamp and voltage errors, the Na+ current was calculated at the po-
tential, which gave the peak inward current. Recordings were discarded if series resistance > 10 MU or deviated by > 20% during
the recording. Linear leak subtraction was performed using P/4 leak subtraction.
Drugs
All solution chemicals were purchased from Sigma-Aldrich. BIIB074 (Axon Medchem) and PF-05089771 (Sigma Aldrich) were dis-
solved in DMSO at 100mM and 1mM, respectively, aliquoted and stored at 20C until the day of use. Cells were bathed in drug
or vehicle for at least 30 min prior to recording.e7 Neuron 101, 905–919.e1–e8, March 6, 2019
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are shown as the mean ± SEM, unless otherwise stated. A Student’s t test was used to compare the mean of two groups and
when data were not normally distributed a non-parametric test was applied (Mann-Whitney). A one-way ANOVA was used when
more than two groups existed. For patch clamp experiments, two-way ANOVA with Holm-Sidak post hoc analysis was used to
assess firing in response to prolonged suprathreshold and graded stimuli. Comparison of rheobase and firing to high-frequency stim-
ulation was tested by Kruskal-Wallis followed by post hoc Dunn’s test. Current densities recorded in heterologous expression sys-
tems were compared by one-way ANOVA followed by post hoc Dunn’s test. Verbal pain intensity ratings and NPS responses
measured by fMRI were compared using a Mann-Whitney U test. Student’s unpaired t test was used to compare SCN9A mRNA
levels. Sample sizes are detailed in each figure legend. Significance for all experiments was placed at p < 0.05. Statistical tests
were carried out with GraphPad prism or SigmaStat.Neuron 101, 905–919.e1–e8, March 6, 2019 e8
